VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016. doi: 10.1016/j.jcf.2016.04.005. [Epub ahead of print]
Jones P, Palser SC, Pravle AP, et al. Secular trends in Pseudomonas aeruginosa acquisition in the United Kingdom: a registry study. J Cystic Fibros. 2016;15(Suppl 1):S31.
Fouhy F, Ronan NJ, O'Sullivan O, et al. Investigating the gut microbiota of patients with cystic fibrosis (PWCF) and the effects of an altered gut microbiota on functionality and faecal metabolites -- the CFMATTERS experience. J Cystic Fibros. 2016;15 (Suppl 1):S12.
Volkova N, Bai Y, Higgins M, et al. Disease progression in patients (pts) with cystic fibrosis (CF) treated with ivacaftor (IVA): analysis of real-world data from the UK CF Registry. J Cystic Fibros. 2016;15(Suppl 1):S41.
Mooney D, Ronan N, Einarsson G, et al. Effect of ivacaftor on airway bacterial community composition in cystic fibrosis patients with the G551D mutation. J Cystic Fibros. 2016;15(Suppl 1):S12.
Sullivan JC, Accurso F, Marigowda G, et al. Improvement in inflammatory biomarkers in patients (pts) with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation treated with lumacaftor (LUM) and ivacaftor (IVA). J Cystic Fibros. 2016;15(Suppl 1):S6.
Smith A, Paisey C, Marchesi J, et al. Age-related evolution of the lower airway microbiome in young children with cystic fibrosis. Bronchoalveolar lavage samples from the CF-SpIT study. J Cystic Fibros. 2016;15(Suppl 1):S11.
Keravec M, Mounier J, Fangous M-S, et al. Pulmotypes of airway microbiota in the early stages of Pseudomonas aeruginosa (Pa) colonization in cystic fibrosis: a cohort study. J Cystic Fibros. 2016;15(Suppl 1):S11.
White H, Shaw NJ, Gillgrass L, et al. What functionality do patients want from an Electronic Clinical Record (ECR)? J Cystic Fibros. 2016;15(Suppl 1):S26–S27.
Rodman J, Krivec U, Jackson A et al. Patient perspectives on electronic access to registry health records: an Irish-Slovene online survey. J Cystic Fibros. 2016;15(Suppl 1):S36.
David V, Pougheon-Bertrand D, Rault G, et al. Adolescence and cystic fibrosis: improving the median FEV1 of adolescents by patient education linked with a quality improvement program. J Cystic Fibros. 2016;15(Suppl 1):S26.
Milla CE, Ratjen F, Marigowda G, et al. Results from an open label Phase 3 study evaluating the safety, tolerability, and pharmacodynamics of combination lumacaftor/ivacaftor (LUM/IVA) therapy in children aged 6 through 11 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation. Presented at: the 39th European Cystic Fibrosis Conference; June 8-11, 2016; Basel, Switzerland.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220-321. Abstract
Elborn JS, Ramsey BW, Boyle MP, et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fi brosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Resp Med. 2016. doi: 10.1016/S2213-2600(16)30121-7. [Epub ahead of print]

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

J. Stuart Elborn, MD

Professor, Queens University Belfast, Belfast, United Kingdom

Disclosures

Disclosure: J. Stuart Elborn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Novartis Pharmaceuticals Corporation; Raptor Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated

Dr Elborn does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Elborn does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Patrick A. Flume, MD

Professor of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina

Disclosures

Disclosure: Patrick A. Flume, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Insmed Incorporated; Novartis Pharmaceuticals Corporation; Pharmaxis Ltd.; Raptor Pharmaceutical, Inc.; Savara, Inc.; Vertex Pharmaceuticals Incorporated
Received grants for clinical research from: Bayer AG; Gilead Sciences, Inc.; Hill-Rom; Insmed Incorporated; Nivalis Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pharmaxis Ltd.; Savara, Inc.; Vertex Pharmaceuticals Incorporated

Dr Flume does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Flume does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Marcia F. Katz, MD

The Brown Foundation Professor of Adult Cystic Fibrosis; Director, Adult Cystic Fibrosis Center, Baylor College of Medicine, Houston, Texas

Disclosures

Disclosure: Marcia F. Katz, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.; Gilead Sciences, Inc.

Dr Katz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Katz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Anders Lindblad, MD

Associate Professor, Queen Silvia Children's Hospital, Department of Pediatrics, Gothenburg, Sweden

Disclosures

Disclosure: Anders Lindblad, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Vertex Pharmaceuticals Incorporated

Dr Lindblad does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lindblad does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Susan Madge, PhD, RN, RSCN

Consultant Nurse, Royal Brompton Hospital, Imperial College, London, United Kingdom

Disclosures

Disclosure: Susan Madge, PhD, RN, RSCN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Madge does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Madge does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Julia Muino, MA

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Views and Perspectives From Basel Switzerland, 2016

Authors: J. Stuart Elborn, MD; Patrick A. Flume, MD; Marcia F. Katz, MD; Susan Madge, PhD, RN, RSCN; Anders Lindblad, MD
CME / ABIM MOC / CE Released: 8/3/2016
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 8/3/2017

Start Activity

Target Audience and Goal Statement

This activity is intended for pulmonologists, pediatricians, nurses, and gastroenterologists.

The goal of this activity is to provide education on recent developments in the management of cystic fibrosis (CF).

Upon completion of this activity, participants will be able to:

Identify the latest clinical data on agents that target pulmonary and infectious symptoms of CF
Outline the potential clinical effect of advances in CF treatment options and strategies

Disclosures

Faculty

J. Stuart Elborn, MD

Professor, Queens University Belfast, Belfast, United Kingdom

Disclosures

Disclosure: J. Stuart Elborn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Novartis Pharmaceuticals Corporation; Raptor Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated

Dr Elborn does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Elborn does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Patrick A. Flume, MD

Professor of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina

Disclosures

Disclosure: Patrick A. Flume, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Insmed Incorporated; Novartis Pharmaceuticals Corporation; Pharmaxis Ltd.; Raptor Pharmaceutical, Inc.; Savara, Inc.; Vertex Pharmaceuticals Incorporated
Received grants for clinical research from: Bayer AG; Gilead Sciences, Inc.; Hill-Rom; Insmed Incorporated; Nivalis Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pharmaxis Ltd.; Savara, Inc.; Vertex Pharmaceuticals Incorporated

Dr Flume does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Flume does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Marcia F. Katz, MD

The Brown Foundation Professor of Adult Cystic Fibrosis; Director, Adult Cystic Fibrosis Center, Baylor College of Medicine, Houston, Texas

Disclosures

Disclosure: Marcia F. Katz, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.; Gilead Sciences, Inc.

Dr Katz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Katz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Anders Lindblad, MD

Associate Professor, Queen Silvia Children's Hospital, Department of Pediatrics, Gothenburg, Sweden

Disclosures

Disclosure: Anders Lindblad, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Vertex Pharmaceuticals Incorporated

Dr Lindblad does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lindblad does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Susan Madge, PhD, RN, RSCN

Consultant Nurse, Royal Brompton Hospital, Imperial College, London, United Kingdom

Disclosures

Disclosure: Susan Madge, PhD, RN, RSCN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Madge does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Madge does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Julia Muino, MA

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Pulmonary Medicine

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Views and Perspectives From Basel Switzerland, 2016

Authors: J. Stuart Elborn, MD; Patrick A. Flume, MD; Marcia F. Katz, MD; Susan Madge, PhD, RN, RSCN; Anders Lindblad, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 8/3/2016

Valid for credit through: 8/3/2017

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Infection and Microbiota of the Lung and Gut

How will these findings influence your practice?
Patrick A. Flume, MD

Section 2. CFTR Modulator Ivacaftor Experience

A summary of key results on mutation-targeting therapies.
Marcia F. Katz, MD

Section 3. Inflammation and the Microbiome

What role do specific microbiota play in CF?
Anders Lindblad, MD

Section 4. Patient Education and Self-Management Tools

What information do patients need to be effective partners in care?
Susan Madge, PhD, RN, RSCN

Section 5. Evaluating Lumacaftor-Ivacaftor Therapy in Young Patients With the Phe508del CFTR Mutation

Late-breaking safety data are reviewed.
J. Stuart Elborn, MD

Page 1 of 6

Infection and Microbiota of the Lung and Gut

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

J. Stuart Elborn, MD

Patrick A. Flume, MD

Marcia F. Katz, MD

Anders Lindblad, MD

Susan Madge, PhD, RN, RSCN

Editor

Julia Muino, MA

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Views and Perspectives From Basel Switzerland, 2016

Target Audience and Goal Statement

Disclosures

Faculty

J. Stuart Elborn, MD

Patrick A. Flume, MD

Marcia F. Katz, MD

Anders Lindblad, MD

Susan Madge, PhD, RN, RSCN

Editor

Julia Muino, MA

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Advances in Cystic Fibrosis: Views and Perspectives From Basel Switzerland, 2016

Contents of This CME Activity

Section 1. Infection and Microbiota of the Lung and Gut

Section 2. CFTR Modulator Ivacaftor Experience

Section 3. Inflammation and the Microbiome

Section 4. Patient Education and Self-Management Tools

Section 5. Evaluating Lumacaftor-Ivacaftor Therapy in Young Patients With the Phe508del CFTR Mutation